STRO:NASDAQ
Sutro Biopharma Inc
$20.48
arrow_downward
-3.89%(-0.83) 1D
$20.48
0.00% (0.00)
bedtimeAfter hours
Closed: Aug 14, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for STRO...
Open
$21.31
High
$21.81
Low
$19.59
Mkt. cap
339.58M
Avg. vol.
321.62K
Volume
448.75K
52-wk high
$43.85
52-wk low
$7.15
EPS
-$17.32
Beta
1.55
Shares outstanding
16.58M
No. of employees
128
Open
$21.31
High
$21.81
Low
$19.59
Mkt. cap
339.58M
Avg. vol.
321.62K
Volume
448.75K
52-wk high
$43.85
52-wk low
$7.15
EPS
-$17.32
Beta
1.55
Shares outstanding
16.58M
No. of employees
128
Profile
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
About Sutro Biopharma Inc
CEO-
Employees128
Founded2003
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitesutrobio.com
AI content may include mistakes. Learn more